Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins

Leukemia and Lymphoma

Volumn 57, Issue 3, 2016, Pages 537-556

  Magarotto, Valeria ^a   Salvini, Marco ^a   Bonello, Francesca ^a   Bringhen, Sara ^a   Palumbo, Antonio ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Daratumumab; Elotuzumab; Monoclonal antibodies; Multiple myeloma; Novel agents; SAR650984; Siltuximab

Indexed keywords

ATACICEPT; AVE 1642; B CELL ACTIVATING FACTOR; BEVACIZUMAB; CD38 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CD74 ANTIGEN; DACETUZUMAB; DARATUMUMAB; ELOTUZUMAB; FIGITUMUMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ISATUXIMAB; LUCATUMUMAB; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN CS1; SILTUXIMAB; SOMATOMEDIN C RECEPTOR; SYNDECAN 1; TABALUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; COMPLEMENT;

CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL ADHESION; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR ESCAPE; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL ADHESION; CLINICAL TRIALS AS TOPIC; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOMODULATION; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 84951276525     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1102245     Document Type: Review

References (87)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
2. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011; 17: 1264-1277.
3. Sherenbenou DW, Behrens CR, Su Y. et al. The development of potential antibody-based therapies for myeloma. Blood Rev 2015; 29: 81-91.
4. Van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and anti-apoptotic signaling pathways in multiple myeloma. Leukemia 2005; 19: 2177-2185.
5. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329-1337.
6. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008; 14: 2775-2784.
7. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552-559.
8. Jakubowiak AJ, Benson DM, Besinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30: 1960-1965.
9. Jakubowiak AJ, Offidani M, Pegourie B, et al. A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2015; 33 (Suppl.):abstr 8573.
10. Usmani SZ, Hoering A, Sexton R, et al. SWOG 1211: a randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM). J Clin Oncol 2014; 32 (Suppl. 5):abstr TPS8624.
11. Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30: 1953-1959.
12. Richardson PG, Jagannath S, Moreau P, et al. Final results for the 1703 Phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2014; 124: 302.
13. Lonial S, Dimopoulos MA, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621-631.
14. Dimopoulos MA, Facon T, Richardson PG, et al. ELOQUENT-1: a phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma. J Clin Oncol 2012; 30 (Suppl.):abstr TPS8113.
15. Reinherz EL, Kung PC, Goldstein G., et al. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci 1980; 77: 1588-1592.
16. Lee HC. Structure and enzymatic functions of Human CD38. Mol Med 2006; 12: 317-323.
17. Chillemi A, Zaccarello G, Quarona V, et al. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med 2013; 19: 99-108.
18. De Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-1848.
19. Gimsing P, Plesner T, Nahi H, et al. A phase I/II, dose-escalation study of daratumumab, A CD38 Mab in patients with multiple myeloma-Preliminary Safety Data. Blood (Suppl) (ASH Annual Meeting Abstracts) 2011; 118:Abstract 1873.
20. Plesner T, Lokhorst HM, Gimsing P, et al. Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: preliminary efficacy data from a multicenter phase I/II study. J Clin Oncol 2012; 30 (Suppl.):abstr 8019.
21. Lokhorst HM, Plesner T, Gimsing P, et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin Oncol 2013; 31 (Suppl.):abstr 8512.
22. Lokhorst HM, Laubach J, Nahi H, et al. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RRMM). J Clin Oncol 2014; 32 (Suppl. 5):abstr 8513.
23. Lonial S, Weiss BM, Usmani SZ, et al. Phase II study of daratumumab (DARA) monotherapy in patients with ≥3 lines of prior therapy or double refractory multiple myeloma (MM). J Clin Oncol 2015; 33 (Suppl.):abstr LBA8512.
24. Plesner T, Arkenau HT, Lokhorst HM, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. J Clin Oncol 2014; 32 (Suppl. 5):abstr 8533.
25. Palumbo A, Dimopoulos MA, Reece DE, et al. Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd] versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM). J Clin Oncol 2015; 33 (Suppl.):abstr TPS8609.
26. Moreau P, Mateos MV, Bladé J, et al. An open label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma. Blood 2014; 124: 176.
27. Mateos MV, Cavo M, Jakubowiak AJ, et al. A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy. J Clin Oncol 2015; 33 (Suppl.):abstr TPS8608.
28. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38 targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38 + hematologic malignancies. Clin Cancer Res 2014; 20: 4574-4583.
29. Van Bueren JL, Jakobs D, Kaldenhoven N. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 2014; 124: 3474.
30. Martin TG, Hsu K, Strickland SA, et al. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. J Clin Oncol 2014; 32 (Suppl. 5):abstr 8532.
31. Martin TG, Baz R, Benson DM, et al. A phase Ib dose escalation trial of SAR650984 (anti-CD38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood (Suppl) 2014; 124: Abstract 83.
32. Wijdenes J, Vooijs WC, Clément C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan 1. Br J Haematol 1996; 94: 318-323.
33. Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, bone cell differentation. Blood 1998; 91: 2679-2688.
34. Tassone B, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytasinoid immunoconjugate B-B4-DMI against CD-138 + multiple myeloma cells. Blood 2004; 104: 3688-3696.
35. Heffner LT, Jagannath S, Zimmerman TM. et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. Blood 2012; 120:Abstract 4042.
36. Kelly KR, Chanan-Khan A, Heffner LT, et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib Blood (Suppl) 2014; 653: Abstract 4736.
37. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognosticcharacteristics of CD56-negative multiple myeloma. Br J Haematol 2002; 117: 882-885.
38. Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56 + multiple myeloma cells. Cancer Res 2004; 64: 4629-4636.
39. Lutz R, Ab O, Foley K, et al. Efficacy of the huN901-DM1 conjugate in combination with antineoplastic agents against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts 2007; (1-Annual-Meeting): 5577.
40. Whiteman K, Ab O, Bartle L, et al. Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts 2008; (1-Annual-Meeting): Abstract 2146.
41. Whiteman K, Johnson H, Xu S, et al., Combination therapy with IMGN901 and lenalidomide plus low-dose dexamethasone is highly effective in multiple myeloma xenograft models. AACR Meeting Abstracts 2009; (2-Annual-Meeting): Abstract 2799.
42. Chanan-Khan A, Wolf JL, Garcia J, et al. Efficacy analysis from Phase I Study of Lorvotuzumab Mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma-A preliminary efficacy analysis. Blood (Suppl) 2010; 116: Abstract 1962.
43. Berdeja JG, Ailawadhi S, Weitman S, et al. Phase I study of lorvotuzumab mertansine (LM,IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed orrelapsed/refractory multiple myeloma. J Clin Oncol 2011; 29 Abstract 8013.
44. Berdeja JG, Hernandez-Ilizaliturri F, Chanan-Khan A, et al. Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in combination with Lenalidomide (Len) and Dexamethasone (Dex) in patients with CD56-Positive relapsed or relapsed/refractory Multiple Myeloma (MM). Blood (Suppl) 2012; 120: 728.
45. Hideshima T, Mitsiades C, Tonon G, et al. UnderstanDing multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
46. Schmidmaier R, Morsdorf K, Baumann P, et al. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers 2006; 21: 218-222.
47. Zheng Y, Yang J, Qian J, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013; 27: 702-710.
48. Veitonmaki N, Hansson M, Zhan F, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 2013; 23: 502-515.
49. Hansson M, Gimsing P, Badros A, et al. A Phase I dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma. Clin Cancer Res 2015; 21: 2730-2736.
50. Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141: 125-39.
51. Hunsucker SA, Magarotto V, Kuhn DJ, Et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011; 152: 579-592.
52. Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009; 145: 481-490.
53. Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013; 161: 357-366.
54. Suzuki K, Ogura M, Abe Y, Suzuki T, et al. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. Int J Hematol 2015; 101: 286-294.
55. Orlowski RZ, Gercheva L, Williams C, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 2015; 90: 42-49.
56. San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014; 123: 4136-4142.
57. Zha J, Lackner MR. Targeting the Insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010; 16: 2512-2517.
58. Descamps G, Gomez-Bougie P, Venot C, et al. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009; 100: 366-369.
59. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
60. Moreau P, Hulin C, Facon T, et al. Phase I Study of AVE1642 Anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Blood (Suppl) 2007;110: Abstract 1166.
61. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor Type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
62. Koldehoff M, Beelen DW, Elmaagacli AH. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. J Leukoc Biol 2008; 84: 561-576.
63. Ria R, Vacca A, Russo F, et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004; 92: 1438-1445.
64. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
65. Li W, Li J, Su C, et al. New targets of PS-341: BAFF and APRIL. Med Oncol 2010; 27: 439-445.
66. Lemancewicz D, Bolkun L, Jablonska E, et al. Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features. Leuk Res 2013; 37: 1089-1093.
67. Fragioudaki M, Tsikaris G, Pappa C, et al. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma. Leuk Res 2012; 36: 1004-1008.
68. Abe M, Kido S, Hiasa M, et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006; 20: 1313-1315.
69. Yaccoby S, Pennisi A, Li X, et al. Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 2008; 22: 406-413.
70. Rossi J, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstroms macroglobulinemia: a phase I study. Br J Cancer 2009; 101: 1051-1058.
71. Manetta J, Bina H, Ryan P, et al. generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res 2014; 7: 121-131.
72. Raje N, Faber EA, Richardson PG, et al. Phase 1 Study of Tabalumab, a Human Anti-BAFF antibody and bortezomib in patients with previously-treated multiple myeloma. Blood (Suppl) 2012; 120: Abstract 447.
73. Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leaDing to cell proliferation and survival. Blood 2006; 107: 4807-4816.
74. Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004; 10: 6606-6611.
75. Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004; 104: 3705-3711.
76. Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol 2013; 163: 478-486.
77. Tai YT, Li X, Tong X, et al. Human Anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005; 65: 5898-5906.
78. Bensinger W, Jagannath S, Becker PS, et al. A Phase 1 dose escalation study of a fully human, antagonist Anti-CD40 antibody, HCD122 (Formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma. Blood (Suppl) 2006; 108: Abstract 3575.
79. Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95: 845-848.
80. Agura E, Niesvizky R, Matous J, et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a Phase 1b Study. Blood (Suppl) 2009; 114: Abstract 2870.
81. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
82. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161: 205-214.
83. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
84. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201.
85. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
86. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 6501-6505.
87. Lesokhin A, Ansell S, Armand P, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood (Suppl) 2014; 624: Abstract 291.